Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Twist Bioscience Corporation has received an average "Moderate Buy" rating from analysts, with a total price target of $48.50 following various rating adjustments from brokerages.
• Insider trading was notable, with CEO Emily M. Leproust selling 31,348 shares at an average price of $32.19, reducing her ownership by 4.96%.
• Recent earnings results showed a loss of ($0.47) per share, outperforming estimates, with a total revenue of $96.06 million for the quarter.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $48.50.

TWST has been the topic of several research analyst reports. Evercore ISI cut their price objective on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Barclays cut their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday.

Insider Activity at Twist Bioscience

In related news, CAO Robert F. Werner sold 2,041 shares of the company's stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $65,699.79. Following the sale, the chief accounting officer directly owned 46,413 shares in the company, valued at approximately $1,494,034.47. This represents a 4.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 31,348 shares of the company's stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the sale, the chief executive officer owned 601,212 shares in the company, valued at $19,353,014.28. The trade was a 4.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,851 shares of company stock worth $1,859,894 over the last quarter. 3.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of TWST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after buying an additional 1,588,587 shares during the last quarter. EdgePoint Investment Group Inc. increased its holdings in shares of Twist Bioscience by 114.3% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock valued at $87,779,000 after acquiring an additional 1,272,732 shares during the last quarter. Nuveen LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at about $31,960,000. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after acquiring an additional 645,730 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company's stock valued at $23,113,000 after acquiring an additional 567,481 shares during the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.89 on Friday. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -21.99 and a beta of 2.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience has a 1 year low of $24.07 and a 1 year high of $55.33. The company's 50 day simple moving average is $27.68 and its 200-day simple moving average is $32.75.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.